Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of BI 44370 TA in Healthy Volunteers
NCT02215759Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jan 2009
- Primary completion
- Jun 2009
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial in migraine comparing BI 44370 TA with Placebo (2 arms). Primary endpoints: Number of patients with adverse events up to 36 days, Number of patients with clinically relevant findings in vital signs and 3 more. Started Jan 2009; status: completed.
02
Drugs
BI 44370
03
Conditions
migraine
Beyond the preview
Go deeper on NCT02215759.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02215759.